Amanote Research
Register
Sign In
Correction: Close and Stable Relationship Between Proliferation and a Hypoxia Metagene in Aromatase Inhibitor-Treated ER-Positive Breast Cancer
Clinical Cancer Research
- United States
doi 10.1158/1078-0432.ccr-11-1325
Full Text
Open PDF
Abstract
Available in
full text
Categories
Cancer Research
Oncology
Date
June 14, 2011
Authors
Unknown
Publisher
American Association for Cancer Research (AACR)
Related search
Accumulation of P53 Is Prognostic for Aromatase Inhibitor Resistance in Early-Stage Postmenopausal Patients With ER-positive Breast Cancer
OncoTargets and Therapy
Oncology
Pharmacology
PCN121 Evaluation of Aromatase Inhibitor Utilization and Failure in Post-Menopausal Women With Advanced ER+/HER2- Breast Cancer
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Glucocorticoid Receptor Modulation Decreases ER-positive Breast Cancer Cell Proliferation and Suppresses Wild-Type and Mutant ER Chromatin Association
Breast Cancer Research
Cancer Research
Oncology
Correction To: Unexpected Benefit From Alpelisib and Fulvestrant in a Woman With Highly Pre-Treated ER-Positive, HER2-Negative PIK3CA Mutant Metastatic Breast Cancer
Clinical Drug Investigation
Medicine
Pharmacology
Pictilisib Plus Anastrozole Reduces Proliferation in ER+ Breast Cancer
Cancer Discovery
Oncology
Guidelines for Osteoprotection in Breast Cancer Patients on an Aromatase Inhibitor
Breast Care
Surgery
Oncology
The mTOR Inhibitor Rapamycin Synergizes With a Fatty Acid Synthase Inhibitor to Induce Cytotoxicity in ER/HER2-Positive Breast Cancer Cells
PLoS ONE
Multidisciplinary
Genetically Engineered ER -Positive Breast Cancer Mouse Models
Endocrine-Related Cancer
Cancer Research
Endocrinology
Oncology
Metabolism
Diabetes
Prohibitin Promotes Androgen Receptor Activation in ER-positive Breast Cancer
Cell Cycle
Medicine
Developmental Biology
Cell Biology
Molecular Biology
